The neurosurgical approach to the management of ischemic stroke has evolved dramatically over the past century with the bulk of these changes occurring over the past 25 years. With recent advances in technology and continued refinements in neurosurgical techniques there has been significant improvement to the safety and efficacy of our treatment options. The focus of this article will be to review the historical and recent reports in the literature related to revascularization techniques.
INTRODUCTION
The neurosurgical approach to the management of ischemic stroke has evolved dramatically over the past century with the bulk of these changes occurring over the past 25 years. While it is true that ischemic strokes continue to have devastating consequences, the modern neurosurgeon has become better equipped than-ever to make a significant impact on the lives of those affected. With recent advances in our fund of knowledge and with new tools in an updated armamentarium, neurosurgeons can now much more frequently not only prevent stroke, but restore blood flow and sometimes even completely restore neurological function to patients in the early stages of a stroke. The use of modern neurosurgical interventions in the management of stroke can be an extremely profound and rewarding experience. To continue to move forward and to fully appreciate the evolution of the newer neurosurgical approaches to the management of ischemic stroke it is important to review some of the historical events which have led to this point. It is also important to point out that a comprehensive review of the scientific and clinical contributions to the management of ischemic stroke would be very vast and would fill many chapters of many textbooks. With that notion in mind, the focus of this article will be specifically on reviewing both historical and current reports in the literature related to revascularization techniques, which are of interest to the field of neurosurgery.
EARLY CAROTID SURGERY
Chiari firmly tied the association between occlusive disease of the carotid arteries and the symptoms of ischemic stroke in 1905 leading to further investigations of potential treatments. 5) 24 ) Chao at the Medical College of Peking performed the first successful surgery aimed at treating carotid occlusion on two people with carotid artery disease and anxiety and depression-like symptoms in 1938. 4) The procedure he described was a carotid artery excision without restoring blood flow. 4) Following the procedure both patient's mental conditions reportedly resolved leading to carotid excision becoming the neurosurgical treatment of choice for occlusion of the carotid artery. 4) Very few subsequent patients improved and it is hypothesized that the improvement reported in successful cases came form prevention of repeat embolization.
Although this procedure was infrequently performed it remained the treatment of choice throughout the 1940's. 18) 24) The first well-documented procedure that successfully restored blood flow to the internal carotid artery was done in Buenos Aires by Carrea, Molina, and Murphy. 25) Angiography revealed severe narrowing of the internal carotid artery above the bifurcation in a patient with symptoms of ischemic stroke. 25) The internal carotid and external carotid artery were cut 5 mm above the lesion. The proximal external carotid artery and distal internal carotid artery were anastomosed and patency was confirmed by angiography. 25) This was the first reported internal-external carotid artery bypass. 25) The patient recovered from hemiparesis and aphasia. 25) This was the first demonstration that returning blood flow to the brain following ischemic stroke could return motor function. While this particular procedure was successful, carotid endarterectomy would soon surpass it to become the technique of choice in the coming years for the management of carotid stenosis. 24) CAROTID ENDARTERECTOMY to do with asymptomatic patients and with patients with moderate stenosis, this therapy was the first neurosurgical procedure that was proven with a randomized controlled trial to have a mortality benefit.
Intravenous tissue plasminogen activator (IV t-PA)
Similar to carotid endarterectomy, the initial trials regarding thrombolytic agents failed to demonstrate benefit and were associated with a marked increased risk of intracranial hemorrhage. as an outcome measure of the ability of patients to function independently they reported that 39% of the patients treated with IV t-PA had a mRS of < 2 at 90 days compared to 26% of patients treated with placebo (OR 1.7, 95% CI 1.1 to 2.6). However, there was a 7% rate of intracranial hemorrhage in the t-PA group compared to a 1% rate in the placebo group. The benefits of improved outcomes at three months outweighed the risk of intracranial hemorrhage in this study. The authors of this study attributed a large part of the differences seen in this study compared to previous studies to the strict limitation of administration of IV t-PA to 3 hours from the time of onset of stroke symptoms. 30) The results of the NINDS study ultimately lead to establishment of the gold standard for the treatment of ischemic stroke being IV t-PA administration for patients presenting within three hours of the onset of symptoms.
Extension of the window
The next major trial that markedly changed the recommendations of stroke management was the ECASS III trial, which specifically looked at extending the window of t-PA. 16) This study compared the outcomes of patients given t-PA during a 3-4.5 hour window to patients given a placebo. Using the mRS with a favorable outcome being defined as a score of 0 or 1, the study showed a relative risk reduction of 1.16 in adverse outcomes (95% CI 1.01 to 1.34, p = 0.04). 16) Further analysis of the of the probability or returning to an independent life style with same variables assessed in the NINDS study (NIHSS, Barthel index, modified
Rankin scale, and Glasgow outcome scale) at 3 months showed a 28% higher chance of returning to an independent lifestyle in the t-PA group compared to placebo (OR 1.28, 95% CI 1.00 to 1.65, p < 0.05).
Intraarterial thrombolytics
A huge hurdle in treatment of ischemic stroke remained what to do with patients with extended times from the onset of symptoms to presentation. It had been demonstrated that after 4.5 hours the harm outweighs the risk of IV tPA. 17) Intraarterial thrombolytics were proposed to improve outcomes in patients who presented too late for IV tPA. The PROACT II trial was a randomized controlled double-blinded trial that was designed to evaluate the efficacy of intraarterial recombinant prourokinase (r-proUK) compared to heparin alone in patients presenting before 6 hours.
13)
The study showed a 60% increase in patients with slight or no neurologic disability at 90 days (40% r-proUK vs. 25% heparin, p = 0.04). 13) This was first study to show a benefit of treating patients outside of the 4.5 hour window, extending the window of possible intervention all the way to 6 hours. While this study showed benefits in improving the quality of life of people who survived, it failed to show any mortality benefit (25% r-proUK vs. 27% heparin) and partially due to a greatly increased rate of symptomatic intracranial hemorrhage rate in the r-proUK group (10% vs. 2%, p = 0.06).
13)

Mechanical Thrombectomy
Initial The trial showed that the Merci ® device achieved recanalization of large vessels in 48% percent of patients treated with the device, which was lower than the 66% achieved with intra-arterial r-proUK. However, this procedure was associated with a lower intracranial hemorrhage rate of 5% compared to 10% in the PROACT-II intra-arterial r-proUK trial. 7.8% with the Merci ® retriever). Despite the increase in hemorrhage, the 90 day mortality was less in the Penumbra ® trial compared to the Merci ® retriever.
31)
The percentage of patients with 90-day mRS of < 2 were very similar (25% Penumbra ® vs. 27.7% Merci ® trial).
29)31)
One potential reason for this failure to achieve better neurologic outcomes is the increased rate of fragmentation of the clot forming distal emboli with the Penumbra ® device compared to the Merci ® clot retriever.
Mechanism
The Penumbra ® system acts differently than the Merci ® retriever in that the device is inserted just proximal clot instead of all the way through it (Fig. 1A) .
Suction is then applied to the Penumbra® device using a vacuum system. A small separator extends from the tip of the device, which can be deployed back and fourth to break up the clot into smaller pieces to facilitate removal by suction (Fig. 1B, C) . A proposed problem with this system has been distal embolization of fragments of the clot. to that of IV t-PA. However, to date no study has had had enough power in the group of patients not treated with t-PA to evaluate this idea. While the stent is deployed reperfusion is also being re-established. After 3 to 5 minutes of deployment the stent device can be closed by withdrawing it into the microcatheter and subsequently removing the entire unit containing the clot, stent and microcatheter out of the patient (Fig. 2C) .
Stent retrievers
A B C Fig. 2. (A, B) show the deployment of a stent retriever. The device and microcatheter are inserted distal to the clot and the microcatheter is withdrawn proximally leaving the stent retriever embedded throughout the clot. (C) shows the stent retriever being withdrawn into the microcatheter carrying the clot after the 3-5 minute waiting period for the clot retriever to stabilize within the clot.
CURRENT ROLE OF MECHANICAL THROMBECTOMY
The early data regarding the efficacy and safety of mechanical thrombectomy supported its usage in patients in which t-PA could not be used. (Table 1 ). All 5 studies randomly assigned patients to receive thrombectomy plus medical care or medical care alone. Before randomization all patients were treated with a standard dose of IV t-PA if eligible.
A recent Meta-analysis of patient data from 570 patients from all five trials and showed a significantly higher the National Institutes of Health Stroke Scale (NIHSS) score after 24 hours as well a greater improvement from baseline to 24 hours NIHSS among all patients assigned to thrombectomy. 15) The Meta-analysis also reported that the 90-day mortality and risk of intraparenchymal hematoma and symptomatic intracranial hemorrhage did not differ between populations. 15) Additionally, a subgroup analysis showed improved outcomes in several subgroups of special interest and years, patients randomized more than 6 hours after symptom onset, and patients not receiving IV t-PA.
15)
Prospects
Mechanical thrombectomy using stent retrievers are 
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